M-PILOCARPINE TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
10-05-2021
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
PILOCARPINE HYDROCHLORIDE
から入手可能:
MANTRA PHARMA INC
ATCコード:
N07AX01
INN（国際名）:
PILOCARPINE
投薬量:
5MG
医薬品形態:
TABLET
構図:
PILOCARPINE HYDROCHLORIDE 5MG
投与経路:
ORAL
パッケージ内のユニット:
15G/50G
処方タイプ:
Prescription
治療領域:
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
製品概要:
Active ingredient group (AIG) number: 0107358009; AHFS:
認証ステータス:
APPROVED
承認日:
2020-02-06
製品の特徴
_M-Pilocarpine Product Monograph_
_Page 1 of 30_
PRODUCT MONOGRAPH
PR
M-PILOCARPINE
PILOCARPINE HYDROCHLORIDE TABLETS, USP
5 MG
CHOLINOMIMETIC AGENT
Mantra Pharma Inc.
9150 Leduc Blvd, Suite 201
Brossard, QC, Canada
J4Y 0E3
Date of Revision:
May 10, 2021
Submission Control No.: 250828
_M-Pilocarpine Product Monograph _
_ _
_Page 2 of 30_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................... 3
SUMMARY PRODUCT INFORMATION
.....................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
................................................................................................
3
WARNINGS AND PRECAUTIONS
..............................................................................
3
ADVERSE REACTIONS
................................................................................................
6
DRUG INTERACTIONS
...............................................................................................
10
DOSAGE AND ADMINISTRATION
...........................................................................
10
OVERDOSAGE
.............................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
......................................................... 12
STORAGE AND STABILITY
......................................................................................
16
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................... 16
PART II: SCIENTIFIC INFORMATION
.............................................................................
17
PHARMACEUTICAL INFORMATION
......................................................................
17
CLINICAL TRIALS
.......................................................................................................
18
DETAILED PHARMACOLOGY
.................................................
完全なドキュメントを読む
